Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases.
作者信息
Macauley Shannon L, Sands Mark S
机构信息
Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
出版信息
Exp Neurol. 2009 Jul;218(1):5-8. doi: 10.1016/j.expneurol.2009.03.040. Epub 2009 Apr 8.
Abstract
摘要
相似文献
1
Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases.用于溶酶体贮积病的有前景的中枢神经系统导向酶替代疗法。
Exp Neurol. 2009 Jul;218(1):5-8. doi: 10.1016/j.expneurol.2009.03.040. Epub 2009 Apr 8.
2
CNS-directed gene therapy for lysosomal storage diseases.用于溶酶体贮积症的中枢神经系统定向基因治疗。
Acta Paediatr. 2008 Apr;97(457):22-7. doi: 10.1111/j.1651-2227.2008.00660.x.
3
Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.靶向溶酶体贮积症的中枢神经系统：血脑屏障穿越的治疗策略。
Mol Ther. 2023 Mar 1;31(3):657-675. doi: 10.1016/j.ymthe.2022.11.015. Epub 2022 Nov 30.
4
Treating lysosomal storage disorders: current practice and future prospects.治疗溶酶体贮积症：当前实践与未来前景
Biochim Biophys Acta. 2009 Apr;1793(4):737-45. doi: 10.1016/j.bbamcr.2008.08.009. Epub 2008 Sep 5.
5
Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.针对溶酶体贮积症的脑靶向基因治疗：突破血脑屏障的新进展
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5760-2. doi: 10.1073/pnas.102175599.
6
Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.用于贮积病的造血干细胞基因治疗：当前及新适应症
Mol Ther. 2017 May 3;25(5):1155-1162. doi: 10.1016/j.ymthe.2017.03.025. Epub 2017 Apr 4.
7
Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases.为神经溶酶体疾病提供造血干细胞基因治疗。
ACS Chem Neurosci. 2019 Jan 16;10(1):18-20. doi: 10.1021/acschemneuro.8b00408. Epub 2018 Aug 23.
8
Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective.酸性鞘磷脂酶缺乏症：临床与免疫学透视。
Int J Mol Sci. 2021 Nov 28;22(23):12870. doi: 10.3390/ijms222312870.
9
ERT Degrades Gene Therapy for Storage Disorder.ERT可降解用于贮积症的基因疗法。
Mol Ther. 2019 Jul 3;27(7):1207-1208. doi: 10.1016/j.ymthe.2019.06.002. Epub 2019 Jun 13.
10
Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.溶酶体酶芳基硫酸酯酶 A 的进化重设计提高了异染性脑白质营养不良的酶替代疗法的疗效。
Hum Mol Genet. 2019 Jun 1;28(11):1810-1821. doi: 10.1093/hmg/ddz020.
引用本文的文献
1
An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.庞贝病中枢神经系统受累的一种新出现的表型：从实验室到临床及其他。
Ann Transl Med. 2019 Jul;7(13):289. doi: 10.21037/atm.2019.04.49.
2
Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease.静脉注射编码人酸性α-葡萄糖苷酶的AAV-PHP.B载体可挽救小鼠庞贝病的肌肉和中枢神经系统缺陷。
Mol Ther Methods Clin Dev. 2019 Jan 25;12:233-245. doi: 10.1016/j.omtm.2019.01.006. eCollection 2019 Mar 15.
3
Infantile Neuroaxonal Dystrophy: Diagnosis and Possible Treatments.婴儿神经轴索性营养不良：诊断与可能的治疗方法
Front Genet. 2018 Dec 10;9:597. doi: 10.3389/fgene.2018.00597. eCollection 2018.
4
Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.溶酶体贮积症的联合疗法：对一个简单问题的复杂解答。
Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1(Suppl 1):639-48.
5
Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.迈向神经元蜡样脂褐质沉积症的有效治疗策略。
Orphanet J Rare Dis. 2016 Apr 16;11:40. doi: 10.1186/s13023-016-0414-2.
6
Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).婴儿神经元蜡样脂褐质沉积症（婴儿型巴滕病）的治疗考量
J Child Neurol. 2013 Sep;28(9):1151-8. doi: 10.1177/0883073813495960.
7
Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).婴儿神经元蜡样脂褐质沉积症（婴儿型CLN1病）的发病机制与治疗方法
Biochim Biophys Acta. 2013 Nov;1832(11):1906-9. doi: 10.1016/j.bbadis.2013.05.026. Epub 2013 Jun 6.
8
Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.经化学修饰的酶对鼠黏多糖贮积症 VII 型神经元储存的优越矫正的生化证据。
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17022-7. doi: 10.1073/pnas.1214779109. Epub 2012 Oct 1.
9
Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy.骨髓移植提高了中枢神经系统定向酶替代疗法在球样细胞脑白质营养不良小鼠模型中的疗效。
Mol Genet Metab. 2012 Sep;107(1-2):186-96. doi: 10.1016/j.ymgme.2012.05.021. Epub 2012 Jun 1.
10
Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease.唾液酸沉积会损害 AAV9 的实用性，但不会损害肽修饰的 AAV 用于溶酶体贮积病小鼠模型的脑基因治疗。
Mol Ther. 2012 Jul;20(7):1393-9. doi: 10.1038/mt.2012.100. Epub 2012 May 15.
本文引用的文献
1
Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse.棕榈酰蛋白硫酯酶1缺陷小鼠的小脑病理学与运动功能障碍
Exp Neurol. 2009 May;217(1):124-35. doi: 10.1016/j.expneurol.2009.01.022. Epub 2009 Feb 10.
2
Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.酶替代疗法可改善异染性脑白质营养不良小鼠模型的共济失调步态和中枢神经系统组织病理学。
Mol Ther. 2009 Apr;17(4):600-6. doi: 10.1038/mt.2008.305. Epub 2009 Jan 27.
3
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease.脑室内注射酸性鞘磷脂酶可纠正尼曼-匹克病A型小鼠模型的中枢神经系统表现。
Exp Neurol. 2009 Feb;215(2):349-57. doi: 10.1016/j.expneurol.2008.10.021. Epub 2008 Nov 14.
4
Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration.尼曼-匹克病A型酸性鞘磷脂酶基因敲除小鼠模型的神经病理学，包括与小脑浦肯野细胞变性相关的结构-功能研究。
Exp Neurol. 2008 Dec;214(2):181-92. doi: 10.1016/j.expneurol.2008.07.026. Epub 2008 Aug 16.
5
Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice.沃尔曼病/胆固醇酯贮积病：植物产生的人溶酶体酸性脂肪酶对小鼠的疗效。
J Lipid Res. 2008 Aug;49(8):1646-57. doi: 10.1194/jlr.M700482-JLR200. Epub 2008 Apr 15.
6
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.脑室内酶替代改善晚期婴儿神经元蜡样脂褐质沉积症小鼠模型的疾病表型。
Mol Ther. 2008 Apr;16(4):649-56. doi: 10.1038/mt.2008.9. Epub 2008 Feb 12.
7
Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse.在尼曼-匹克病A型小鼠中，脑实质内注射酸性鞘磷脂酶可导致溶酶体贮积病理的局部纠正。
Exp Neurol. 2007 Oct;207(2):258-66. doi: 10.1016/j.expneurol.2007.06.017. Epub 2007 Jul 10.
8
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.治疗干预的时机决定了晚发性婴儿型贝敦氏病小鼠模型的功能和生存结果。
Mol Ther. 2007 Oct;15(10):1782-8. doi: 10.1038/sj.mt.6300249. Epub 2007 Jul 17.
9
The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.酸性鞘磷脂酶缺乏型尼曼-匹克病的发病机制与治疗
J Inherit Metab Dis. 2007 Oct;30(5):654-63. doi: 10.1007/s10545-007-0632-9. Epub 2007 Jul 12.
10
Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse.在尼曼-匹克病小鼠模型中，联合进行脑部和全身的腺相关病毒（AAV）注射可带来最大的功能改善和生存益处。
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9505-10. doi: 10.1073/pnas.0703509104. Epub 2007 May 21.
Zotero 插件